| 华北制药股份有限公司2025 年半年度报告摘要 | | | | | --- | --- | --- | --- | | 公司代码：600812 公司简称：华北制药 | | | | | 华北制药股份有限公司 | | | | | 年半年度报告摘要 | 华北制药股份有限公司2025 | | | | 第一节 | 重要提示 | | | | 展规划，投资者应当到 网站仔细阅读半年度报告全文。 | www.sse.com.cn | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 报告期内，公司无半年度利润分配预案或资本公积金转增股本预案。 | | | | | 第二节 | 公司基本情况 | | | | 公司股票简况 | | | | | 股票种类 | 股票上市交易所 | 股票简称 | 股票代码 变更前股 | | 票简称 | | | | | A股 | 上海证券交易所 华北制药 | | 600812 无 | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | 姓名 | 肖志广 | 杨静 | | | 电话 | 0311-87173756 | 0311-8 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-045 华北制药股份有限公司 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年半年度报告》和《2025 年 半年度报告摘要》。 表决结果：同意 9 票； 反对 0 票； 弃权 0 票。 上述议案已经董事会审计委员会审议通过，并同意提交公司董事会审 议。 （二）审议通过《关于冀中能源集团财务有限责任公司的风险持续评 估报告》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 二次会议于 2025 年 8 月 1 日向全体董事、监事及公司高级管理人员以电子 邮件形式发出会议通知，以现场表决方式于 2025 年 8 月 13 日在公司会议 室召开。本次会议应出席董事 9 名，实际出席董事 9 名，会议由董事长王 立鑫先生主持。会议的召集、召开和表决程序符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司 ...

Core Viewpoint - The report evaluates the financial risk and operational status of Jizhong Energy Group Financial Co., Ltd., highlighting its compliance, risk management, and financial performance as of June 30, 2025 [1][13]. Financial Company Overview - Jizhong Energy Group Financial Co., Ltd. was established in 1998 and has undergone several capital increases, with a current registered capital of 55 billion RMB [1][3]. - The company has three main shareholders: Jizhong Energy Group, Jizhong Energy Co., Ltd., and North China Pharmaceutical Group, with respective ownership stakes of 45%, 35%, and 20% [2][3]. Compliance and Risk Control - The financial company operates under a robust governance structure, including a board of directors and various departments dedicated to risk control and internal auditing [4][12]. - It adheres to strict internal control measures and regulatory requirements, ensuring compliance with national financial regulations [5][12]. Operational Performance - As of June 30, 2025, the financial company reported total assets of 202.90 billion RMB and total liabilities of 142.28 billion RMB, with a net profit of 1.31 billion RMB for the first half of 2025 [13]. - The company maintains a capital adequacy ratio of 30.54% and a liquidity ratio of 65.78%, indicating strong financial health [13]. Risk Management Practices - The financial company has established comprehensive risk management policies, including credit risk assessment and monitoring systems for its lending activities [8][9]. - It has implemented various management measures to prevent internal operational risks and ensure the safety of client funds [6][7]. Shareholder Transactions - As of June 30, 2025, the shareholders' deposits and loans with the financial company were reported, with North China Pharmaceutical Group having a deposit balance of approximately 39.37 million RMB [14][16]. - The company has facilitated significant transactions, including commercial bill discounts totaling 4 billion RMB for North China Pharmaceutical Group [15]. Risk Assessment Conclusion - The financial company is deemed to operate within legal frameworks, with no significant violations of financial regulations reported [17]. - It has maintained a high level of loan loss provisions, ensuring that all member units are able to meet their repayment obligations without delays [17].

Group 1 - The company reported a revenue of 5.275 billion yuan for the first half of 2025, representing a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders of the listed company was 123 million yuan, showing a significant year-on-year increase of 71.56% [1] - The basic earnings per share were 0.072 yuan [1]

华北制药股份有限公司 关于冀中能源集团财务有限责任公司的 风险持续评估报告 根据《上海证券交易所上市公司自律监管指引第5号— —交易与关联交易》的要求，华北制药股份有限公司(以下简 称"华北制药"或"公司")通过查验冀中能源集团财务有限 责任公司（以下简称"财务公司"）的《金融许可证》、《企 业法人营业执照》等证件资料，并审阅包括资产负债表、利 润表、现金流量表等在内的财务公司的定期财务报告，对其 经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、财务公司基本情况 财务公司前身为华北制药集团财务有限责任公司，是经 中国人民银行（银复[1993]245号）批准成立，1998年8月18 日 取 得 《 企 业 法 人 营 业 执 照 》 （ 统 一 社 会 信 用 代 码 91130000104337206A）。2009年，依据冀国资字[2009]84号 文件要求，冀中能源集团有限责任公司（以下简称"冀中能 源集团"）对华北制药集团有限责任公司实施了战略重组， 并收购其持有华北制药集团财务有限责任公司的股份成为 华北制药集团财务有限责任公司股东。2009年，经中国银行 业监督管理委员会河北监管局（银监冀 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-045 华北制药股份有限公司 第十一届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 二次会议于 2025 年 8 月 1 日向全体董事、监事及公司高级管理人员以电子 邮件形式发出会议通知，以现场表决方式于 2025 年 8 月 13 日在公司会议 室召开。本次会议应出席董事 9 名，实际出席董事 9 名，会议由董事长王 立鑫先生主持。会议的召集、召开和表决程序符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《2025年半年度报告全文及摘要》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年半年度报告》和《2025 年 半年度报告摘要》。 表决结果：同意 9 票； 反 ...

Financial Performance - Basic earnings per share for the first half of 2025 increased by 71.43% to CNY 0.072 compared to CNY 0.042 in the same period last year[22]. - Diluted earnings per share also rose by 71.43% to CNY 0.072 from CNY 0.042 year-on-year[22]. - The net profit attributable to shareholders of the listed company increased significantly, driven by enhanced budget control and lean management practices[22]. - The weighted average return on net assets improved by 0.93 percentage points to 2.266% from 1.340% in the previous year[22]. - The basic earnings per share after deducting non-recurring gains and losses increased by 118.75% to CNY 0.070 from CNY 0.032 year-on-year[22]. - The weighted average return on net assets after deducting non-recurring gains and losses increased by 1.18 percentage points to 2.199% from 1.020%[22]. - The total profit increased, reflecting the company's efforts in cost reduction and efficiency improvement measures[22]. - Total profit for the same period reached RMB 214 million, reflecting a significant growth of 42.68% compared to the previous year[25]. - Net profit attributable to shareholders was RMB 123.5 million, up 71.56% year-on-year[25]. - The net profit after deducting non-recurring gains and losses was RMB 119.9 million, representing a 120.69% increase from the previous year[25]. Revenue and Cash Flow - The company's operating revenue for the first half of 2025 was RMB 5.28 billion, a year-on-year increase of 0.84%[25]. - The company's net cash flow from operating activities decreased by 44.35% to RMB 491.5 million[25]. - Cash inflow from investment activities was ¥60,008,200.00 in the first half of 2025, compared to ¥1,256,500.00 in the same period of 2024, showing a substantial increase[114]. - Cash outflow from investment activities totaled ¥235,625,353.31 in the first half of 2025, down from ¥328,681,651.53 in the first half of 2024, indicating a decrease of about 28.3%[114]. - The net cash flow from financing activities was -¥514,056,160.34 in the first half of 2025, compared to a positive cash flow of ¥356,142,997.81 in the same period of 2024[114]. Assets and Liabilities - As of the end of the reporting period, the net assets attributable to shareholders were RMB 5.47 billion, an increase of 1.44% from the previous year[25]. - Total assets at the end of the reporting period amounted to RMB 21.75 billion, up 1.31% from the previous year[25]. - Total liabilities amounted to ¥13,702,975,739.11, compared to ¥13,257,882,326.66 in the previous year, indicating a growth of 3.35%[105]. - Total current assets as of June 30, 2025, amounted to ¥8,564,390,541.75, an increase from ¥8,259,279,869.84 at the end of the previous year[100]. - Current liabilities rose to ¥12,108,718,070.56 from ¥10,961,529,998.42, indicating an increase of approximately 10.5%[101]. Research and Development - R&D investment for the first half of the year was CNY 456 million, with an R&D intensity of 8.64%[35]. - The company launched multiple generic drug projects in fields such as anti-infection and cardiovascular diseases, with several products approved for clinical trials[35]. - Research and development expenses increased to ¥169,073,874.09, up 5.9% from ¥160,550,724.60 in the previous year[108]. Market and Industry Context - The pharmaceutical manufacturing industry is facing pressures of overall weakness and profit decline, with a projected revenue decrease of 1.2% for the first half of 2025[31]. - The company is focusing on high-value and high-growth projects, particularly in the biopharmaceutical sector, while consolidating its chemical drug business[28]. - The company achieved export revenue of CNY 1.10 billion in the first half of the year, focusing on high-end markets in Japan and completing orders in Thailand and the Philippines[34]. Corporate Governance and Compliance - There were no major risks that materially affected the company's operations during the reporting period[8]. - The company has maintained compliance with all relevant laws and regulations, ensuring no non-operational use of funds by shareholders or related parties[70]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[66]. Community and Environmental Initiatives - The company is implementing a rural revitalization plan, deploying 6 team members to support poverty alleviation efforts in specific villages[60]. - The company is focusing on industry assistance by planning deep processing of crops to increase income and create local employment opportunities[60]. - The company has completed various community service projects, including repairing damaged infrastructure and enhancing public services in the villages[60]. Shareholder Information - Total number of common shareholders as of the end of the reporting period is 83,985[86]. - The largest shareholder, Jizhong Energy Co., Ltd., holds 413,080,473 shares, representing 24.08% of total shares[88]. - The total number of shares held by the top ten shareholders accounts for a significant portion of the company's equity, with the top three alone holding over 55%[88]. Financial Instruments and Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[133]. - The company will implement new accounting standards starting January 1, 2024, with no significant impact on the financial statements expected[132]. - Financial assets will be classified based on the business model and cash flow characteristics, including those measured at amortized cost and fair value[152].

Core Viewpoint - North China Pharmaceutical (600812.SH) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating strong financial performance despite a modest revenue growth [1] Financial Performance - The company achieved an operating revenue of 5.275 billion yuan, representing a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders reached 123 million yuan, showing a substantial year-on-year increase of 71.56% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 120 million yuan, reflecting a remarkable year-on-year growth of 120.69% [1] - Basic earnings per share were reported at 0.072 yuan [1]

华北制药公告，2025年上半年营业收入52.75亿元，同比增长0.84%。净利润1.23亿元，同比增长 71.56%。基本每股收益0.072元／股，同比增长71.43%。 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of North China Pharmaceutical Co., Ltd. as of August 13, 2025, indicating a stock price of 6.9 yuan, a slight increase of 0.29%, and a trading volume of 602,000 hands with a transaction amount of 415 million yuan [1] - The company reported total revenue of 2.574 billion yuan for Q1 2025, reflecting a year-on-year growth of 0.65%, while net profit attributable to shareholders reached 57.49 million yuan, showing a significant increase of 216.72% [1] - The company has a current ratio of 0.731, a quick ratio of 0.532, and a debt-to-asset ratio of 69.30%, indicating its liquidity and financial leverage status [1] Group 2 - North China Pharmaceutical has made investments in 45 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 642 trademark registrations and 139 patents, along with 349 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]